Reading view
Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine
BMC Cancer. 2025 Dec 15. doi: 10.1186/s12885-025-15341-z. Online ahead of print.
NO ABSTRACT
PMID:41398222 | DOI:10.1186/s12885-025-15341-z
Identification of C4BPA as a genetically informed drug target in NSCLC: an integrative single-cell and multi-omics study based on the druggable genes
Hum Genomics. 2025 Oct 6;19(1):113. doi: 10.1186/s40246-025-00829-3.
ABSTRACT
BACKGROUND: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advancements in treatment, drug resistance and limited therapeutic efficacy persist, underscoring the urgent need for novel and mechanistically informed therapeutic strategies. Identifying genetically supported drug targets may accelerate the development of precision therapies in NSCLC.
METHODS: We implemented an integrative multi-omics framework combining single-cell RNA sequencing (scRNA-seq), genome-wide association studies (GWAS), and molecular quantitative trait locus (QTL) datasets including expression (eQTL), protein (pQTL), and DNA methylation (mQTL) QTLs. Druggable candidates were systematically evaluated using a suite of Mendelian randomization (MR) approaches-including summary data-based MR (SMR), generalized SMR (GSMR), and genetic risk score (GRS) analysis. Epigenetic regulation and downstream signaling were further explored through mediation MR analysis.
RESULTS: C4BPA, a complement-regulatory macromolecule, emerged as a risk factor for NSCLC across multiple MR models, with consistent findings validated at both transcriptomic and proteomic levels. Epigenetic activation of C4BPA via DNA methylation was observed, and C4BPA expression was shown to promote NSCLC progression through the inflammatory chemokine CCL8 signaling axis. Sensitivity analyses confirmed the robustness of association inference.
CONCLUSIONS: Our findings identify C4BPA as a genetically validated and biologically plausible therapeutic target for NSCLC. This study demonstrates the power of integrating single-cell transcriptomics with population-scale omics and association inference to uncover actionable targets, offering a scalable framework for advancing precision oncology in lung cancer.
PMID:41053817 | PMC:PMC12502296 | DOI:10.1186/s40246-025-00829-3
Acyl post-translational modification of proteins by metabolites in cancer cells
Cell Death Discovery, Published online: 21 May 2025; doi:10.1038/s41420-025-02535-4
Acyl post-translational modification of proteins by metabolites in cancer cellsLiquid biopsies in cancer
Mol Biomed. 2025 Mar 20;6(1):18. doi: 10.1186/s43556-025-00257-8.
ABSTRACT
Cancer ranks among the most lethal diseases worldwide. Tissue biopsy is currently the primary method for the diagnosis and biological analysis of various solid tumors. However, this method has some disadvantages related to insufficient tissue specimen collection and intratumoral heterogeneity. Liquid biopsy is a noninvasive approach for identifying cancer-related biomarkers in peripheral blood, which allows for repetitive sampling across multiple time points. In the field of liquid biopsy, representative biomarkers include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. Many studies have evaluated the prognostic and predictive roles of CTCs and ctDNA in various solid tumors. Although these studies have limitations, the results of most studies appear to consistently demonstrate the correlations of high CTC counts and ctDNA mutations with lower survival rates in cancer patients. Similarly, a reduction in CTC counts throughout therapy may be a potential prognostic indicator related to treatment response in advanced cancer patients. Moreover, the biochemical characteristics of CTCs and ctDNA can provide information about tumor biology as well as resistance mechanisms against targeted therapy. This review discusses the current clinical applications of liquid biopsy in cancer patients, emphasizing its possible utility in outcome prediction and treatment decision-making.
PMID:40108089 | PMC:PMC11923355 | DOI:10.1186/s43556-025-00257-8
Aspirin prevents metastasis by limiting platelet TXA<sub>2</sub> suppression of T cell immunity
Nature, Published online: 05 March 2025; doi:10.1038/s41586-025-08626-7
Inhibition of cyclooxygenase 1 releases T cells from immunosuppression by platelet-derived thromboxane A2, thereby enhancing the immune response against metastasis.Author Correction: An engineered influenza virus to deliver antigens for lung cancer vaccination
Nature Biotechnology, Published online: 13 July 2023; doi:10.1038/s41587-023-01884-8
Author Correction: An engineered influenza virus to deliver antigens for lung cancer vaccinationAn engineered influenza virus to deliver antigens for lung cancer vaccination
Nature Biotechnology, Published online: 25 May 2023; doi:10.1038/s41587-023-01796-7
A cancer vaccine is delivered to the lung by an engineered attenuated influenza virus.Nanobody-tethered transposition enables multifactorial chromatin profiling at single-cell resolution
Nature Biotechnology, Published online: 19 December 2022; doi:10.1038/s41587-022-01588-5
Cell surface protein expression and multiple epigenetic features are mapped simultaneously in single cells.